Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2018’, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis)

- The report reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Burkholderia pseudomallei Infections (Melioidosis) therapeutics and enlists all their major and minor projects

- The report assesses Burkholderia pseudomallei Infections (Melioidosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bavarian Nordic A/S

Emergent BioSolutions Inc

Grifols SA

MerLion Pharmaceuticals Pte Ltd

Soligenix Inc

Syntiron LLC

Bavarian Nordic A/S

Emergent BioSolutions Inc

Grifols SA

MerLion Pharmaceuticals Pte Ltd

Soligenix Inc

Syntiron LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Burkholderia pseudomallei Infections (Melioidosis) - Overview

Burkholderia pseudomallei Infections (Melioidosis) ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Burkholderia pseudomallei Infections (Melioidosis) - Overview

Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development

Bavarian Nordic A/S

Emergent BioSolutions Inc

Grifols SA

MerLion Pharmaceuticals Pte Ltd

Soligenix Inc

Syntiron LLC

Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles

ARD-3100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-3150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia pseudomallei vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FG-LpxC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-072 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melioidosis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGX-943 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects

Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products

Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones

Featured News & Press Releases

Nov 27, 2017: Soligenix Announces Presentation of Data on Dusquetide at Chemical and Biological Defense Science and Technology Conference

Jun 28, 2017: MerLion and Dstl Awarded DTRA Grant to Explore the Use of Finafloxacin against Biological Threat Agents

May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis

Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Aug 14, 2014: US DTRA to fund preclinical work on Evolva’s antibiotic GC-072

Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development

Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H1 2018

Number of Products under Development by Companies, H1 2018

Number ...

List of Tables

Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bavarian Nordic A/S, H1 2018

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Emergent BioSolutions Inc, H1 2018

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Grifols SA, H1 2018

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2018

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, H1 2018

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Syntiron LLC, H1 2018

Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H1 2018

Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H1 2018

Number of Products under Development by Companies, H1 2018

Number ...

List of Figures

Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports